A novel intrauterine stent for prevention of intrauterine adhesions
Intrauterine adhesions (IUAs), also known as Asherman syndrome, was first reported by Asherman in 1894 (1). The prevalence ranges from 1.73% to 40%, and the symptoms include hypomenorrhea, amenorrhea, and periodic lower quadrant abdominal pain. IUAs affect pregnancy, having various presentations; for example, infertility, repeated pregnancy loss, poor implantation, and abnormal placentation (2-6). Surgery has been the standard treatment choice for the management of Asherman syndrome. Since surgical wounds are prone to re-adhesion, the postoperative recurrence rate is as high as 3.1–62.5% (2,7-8). In practice, surgeons have tried to use a series of solid and semi-solid barriers as secondary prevention strategies to supply an artificial interlayer between the uterine walls to prevent their fusion during the initial healing phase.